Mizuho on Fate Therapeutics (FATE): 'setting up as a key year for the story'
Tweet Send to a Friend
Mizuho analyst Mara Goldstein reiterated an Outperform rating and $8.00 price target on Fate Therapeutics (NASDAQ: FATE).The analyst comments "FATE ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
